

ANTICOAGULATION

Berthier AM, Pommereuil M, Morel H, **Amiral J**, Martinoli JL.

Comparison of immunological (ELISA) and biological determination of factor X in oral anticoagulant therapy.

Haemostasis, 12 (1-2): 142; 1982.

Berthier AM, Pommereuil M, **Amiral J**, Martinoli JL.

Dosage immunoenzymatique et fonctionnel du facteur X: étude comparative au cours des traitements anticoagulants oraux.

Feuil. Biol. 28 (157): 17-22, 1987.

DVTENOX study group : Alexandre P, **Amiral J**, Bienvendu J, Borg JY, Bridey F, Cahan L, Combe S, Delahousse B, Dreyfus M, Gauthier C, Juhan-Vague I, Landauer D, Musitelli JJ, Pouzol P, Raïsky F, Reynaud J, Sie P, Sitbon O, Treziac MC.

Markers of hemostatic system activation in acute deep venous thrombosis : evolution during the first days of heparin treatment.

Thromb. Haemostasis 70(6), 909-914, 1993.

Iyer L, Adam M, **Amiral J**, Fareed J, Bermes E.

Development and validation of two enzyme-linked immunosorbent assay (Elisa) methods for recombinant hirudin.

Semin. Thromb. Haemostasis 21 (2): 184-192, 1995 .

Amiral J.

Usefulness of laboratory techniques for evaluating antithrombotic efficacy of new therapeutic strategies.

Clin. Appl. Thromb. Hemost. 1 (4): 243-259, 1995.

Falkon L, Gari M, Barbanoj M, **Amiral J**, Fontcuberta J.

Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses.

Blood Coag Fibrinolysis 9(2): 137-141; 1998.

M M Samama; **J Amiral**; C Guinet; E Perzborn; F Depasse

An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma

Thromb Haemostas 2010 ; 1204(5) ; 1078-79

MM Samama, **J Amiral**, C Guinet, L Le Flem, and J Seghatchian

Monitoring plasma levels of factor Xa inhibitors: how, why and when?

Expert review Hematol; 2013; 6(2); 155-64

J Amiral, C Dunois, C Amiral, J Seghatchian

An update on laboratory measurements of Dabigatran: Smart specific and calibrated dedicated assays for measuring anti-IIa activity in plasma

Transfusion and Apheresis Science 2016; 54; 428–437

B I Eriksson, Z Mikuska, M Feuring, **J Amiral**, S Haertter, J Stangier, G Nehmiz, J I. Weitz

An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery

Thrombosis Research 144 (2016) 158–164

J Amiral, C Dunois, C Amiral, J Seghatchian

Anti-Xa bioassays for the laboratory measurement of direct Factor Xa inhibitors in plasma, in selected patients

Transfusion and Apheresis Science 2016; 55 ; 249–261